Clinical Trials Arena is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Otezla (apremilast) for the Treatment of Active Psoriatic Arthritis

Drug Name (Brand / Generic)

Otezla / apremilast

Developed by

Celgene Corporation

Therapy Class

Anti-inflammatory drugs

Product Description

Phosphodiesterase-4 inhibitor

Current Indication

Active psoriatic arthritis (PsA) and Psoriasis

Market Sector

Rheumatology and dermatology

Development Status

Approved in the US
Expand
Close
Close
Close

Go Top